Price List - Itovebi - Oncological Agents - Breast Cancer.xlsx
XLSX spreadsheet 46 KB Posted
- Solicitation number
- HT9402-25-Q-9102
- Issued by
-
Defense Health Agency
About this file
This file is a pricing template spreadsheet for pharmaceutical manufacturers to submit quotes for breast cancer oncological agents being considered for the Department of Defense (DoD) Uniform Formulary. The template is structured to collect pricing information for up to 10 newly approved drugs that will be reviewed at the February 5-6, 2025 DoD Pharmacy & Therapeutics Committee meeting, with quotes due by December 19, 2024.
The template includes sections for both Blanket Purchase Agreement (BPA) pricing and Additional Discount Program (ADP) pricing, allowing manufacturers to submit pricing scenarios for uniform formulary vs. non-formulary status at Military Treatment Facilities and Mail Order, as well as Tier 2 vs. Tier 3 retail pricing. Manufacturers must provide NDC numbers, drug names, strengths, dosage forms, package sizes, and pricing information including Federal Ceiling Prices (FCP), non-FAMP prices, WAC prices, and proposed discounts. The pricing submission will support the DoD's evaluation of relative clinical and cost effectiveness for placing these agents on the DoD Uniform Formulary.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Price Appendix FAQ NAD.pdf | ||
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Miplyffa - Neurological Agents Miscellaneous - NA.xlsx | XLSX spreadsheet | |
| RFQ HT9402-25-Q-9102 NAD.pdf | ||
| Price List - Opipza - Antipsychotic Agents - Atypical.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the February 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 |
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 252OABCG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 252OABCG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 252OABCG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 252OABCG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 252OABCG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 252OABCG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 252OABCG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 252OABCG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 252OABCG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 252OABCG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 252OABCG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 252OABCG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 252OABCG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 252OABCG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 252OABCG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 252OABCG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 252OABCG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 252OABCG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 252OABCG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 252OABCG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the February 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 |
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the February 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 |
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | Feb 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | BREAST CANCER | Quotes due: | December 19, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 252OABCG1T21M | Tier 2 | 1 or more | |
| 252OABCG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .